FIGURE

Figure 2

ID

ZDB-FIG-230416-97

Publication

Badenetti et al., 2023 - Monitoring Nrf2/ARE Pathway Activity with a New Zebrafish Reporter System

Other Figures

All Figure Page

Back to All Figure Page

Figure 2

Pharmacological validation of Nrf2/ARE reporter fish. (A) Whole-mount bright field and fluorescence microscopy acquisition of a 24 hpf transgenic larva treated with DMSO and the Nrf2 pathway agonist, RTA-408, for 16 h. A significant increase in fluorescent cells is detected in RTA-408-treated larvae when compared to DMSO-treated fish. (B) Whole-mount bright field and fluorescence microscopy acquisition of a 24 hpf transgenic larva treated with DMSO and the Nrf2 pathway antagonist, Brusatol, for 16 h. A visible decrease in reporter fluorescent intensity is visible in Brusatol-treated larvae. All images are lateral views with anterior to the left. The magnifications of the trunk regions are confocal Z-stack acquisitions. The graphs reported on the right depict the ImageJ-based quantification of the selected trunk region of 5 independently treated fish (* p < 0.05; ** p < 0.005, t-test). Scale bars in the panels with multiple fish: 500 μm; scale bars on the panels with a single magnified larva: 100 μm.

Expression Data

Expression Detail

Antibody Labeling

Phenotype Data

Phenotype Detail

Acknowledgments

This image is the copyrighted work of the attributed author or publisher, and ZFIN has permission only to display this image to its users. Additional permissions should be obtained from the applicable author or publisher of the image. Full text @ Int. J. Mol. Sci.